Breaking News Instant updates and real-time market news.

VKTX

Viking Therapeutics

$11.73

-0.605 (-4.91%)

18:57
11/12/18
11/12
18:57
11/12/18
18:57

Viking Therapeutics says VK2809 study achieves primary, secondary endpoints

Viking Therapeutics announced the presentation of results from the company's 12-week Phase 2 study of VK2809, its novel liver-selective thyroid receptor beta agonist, in patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. As previously reported, the study successfully achieved both its primary and secondary endpoints, and demonstrated an encouraging safety and tolerability profile. Newly presented data provide further detail on the trial endpoints, highlighting the changes to LDL-C, atherogenic proteins, and other liver parameters. The results were presented Monday, November 12 as part of the Oral Late-Breaker session of The Liver Meeting 2018, the annual meeting of the American Association for the Study of Liver Diseases, held November 9-13 in San Francisco, CA.

  • 13

    Nov

VKTX Viking Therapeutics
$11.73

-0.605 (-4.91%)

09/21/18
RAJA
09/21/18
NO CHANGE
Target $43
RAJA
Outperform
Raymond James says Viking volatility on GTx trial failure would be chance to buy
Raymond James analyst Steven Seedhouse would be a buyer on any volatility in Viking Therapeutics (VKTX) after GTx (GTXI) announced its Phase 2 ASTRID study testing enobosarm in women with SUI failed to achieve its primary endpoint. Viking has not ever tested VK5211 in SUI, but there had appeared to be solid early clinical and preclinical rationale for the indication, Seedhouse tells investors. Viking is not yet developing its SARM VK5211 in SUI and VK5211 is not in his model for either SUI or hip fracture recovery, so the failure of ASTRID really doesn't have immediate or direct negative readthrough to Viking, Seedhouse added. He maintains an Outperform rating and $43 price target on Viking shares, which are down 1% to $18.73 in early trading.
10/01/18
HCWC
10/01/18
NO CHANGE
Target $31
HCWC
Buy
Viking Therapeutics price target raised to $31 from $28 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Viking Therapeutics to $31 after the company and investigators presented updated VK5211 data in an oral plenary presentation at the American Society of Bone and Mineral Research. The key takeaways from the VK5211 Phase 2 data in hip fracture patients include: VK5211 produces significant muscle growth in hip fracture patients, VK5211-treated patients experienced overall weight gain, the six-minute walk test demonstrated a trend favoring the treatment arms and the tolerability profile in elderly patients was encouraging with no treatment-emergent adverse events, Pantginis tells investors in a research note. The analyst keeps a Buy rating on Viking Therapeutics.
10/01/18
WBLR
10/01/18
NO CHANGE
WBLR
Outperform
Viking Therapeutics data increase partnership potential, says William Blair
Viking Therapeutics over the weekend at the American Society for Bone and Mineral Research annual meeting presented full data from the positive Phase II study with VK5211 for the treatment of patients recovering from hip fracture, William Blair analyst Andy Hsieh tells investors in a research note. While top-line results were released late last year, there were incrementally positive data points, including 6-minute walk test improvements and "intriguing" fat mass reduction, Hsieh writes. He believes the updated clinical profile bodes well for the partnership potential for VK5211 and eventual market uptake. The analyst continues to hold a bullish view on Viking Therapeutics shares with an Outperform rating.
10/02/18
HCWC
10/02/18
NO CHANGE
Target $280
HCWC
Buy
Ligand price target raised to $280 from $270 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals (LGND) to $280 after Viking Therapeutics (VKTX) and investigators presented updated VK5211 data in an oral plenary presentation at the American Society of Bone and Mineral Research meeting. VK5211 produces significant muscle growth in hip fracture patients and treated patients experienced overall weight gain, with loss of body fat, Pantginis tells investors in a research note. The analyst believes the chances for an outright acquisition of Viking has increased with VK2809 and VK5211 having the potential to address very large markets. He keeps a Buy rating on Ligand.

TODAY'S FREE FLY STORIES

COMM

CommScope

$25.99

-0.4 (-1.52%)

07:07
04/22/19
04/22
07:07
04/22/19
07:07
Upgrade
CommScope rating change  »

CommScope reinstated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISRG

Intuitive Surgical

$528.04

3.29 (0.63%)

07:07
04/22/19
04/22
07:07
04/22/19
07:07
Recommendations
Intuitive Surgical analyst commentary  »

Intuitive Surgical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

CCBG

Capital City Bank

$23.48

0.1 (0.43%)

07:06
04/22/19
04/22
07:06
04/22/19
07:06
Earnings
Capital City Bank reports Q1 EPS 38c, consensus 37c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

RCII

Rent-A-Center

$21.35

0.07 (0.33%)

07:05
04/22/19
04/22
07:05
04/22/19
07:05
Hot Stocks
Rent-A-Center ends all further litigation with Vintage Capital, B. Riley »

Rent-A-Center announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:05
04/22/19
04/22
07:05
04/22/19
07:05
General news
S&P 500 futures are down 0.2% »

S&P 500 futures…

TGT

Target

$83.23

0.51 (0.62%)

07:04
04/22/19
04/22
07:04
04/22/19
07:04
Hot Stocks
Target introduces household essentials brand called Everspring »

Target announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTIL

Precision BioSciences

$12.15

-0.84 (-6.47%)

07:04
04/22/19
04/22
07:04
04/22/19
07:04
Initiation
Precision BioSciences initiated  »

Precision BioSciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$178.28

-0.49 (-0.27%)

07:04
04/22/19
04/22
07:04
04/22/19
07:04
Periodicals
Facebook willing to extempt EU parties from some ad rules, FT reports »

Facebook is willing to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 03

    Jun

STLD

Steel Dynamics

$33.99

-0.16 (-0.47%)

07:03
04/22/19
04/22
07:03
04/22/19
07:03
Hot Stocks
Steel Dynamics believes North American steel consumption will grow »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 16

    May

ST

Sensata

$51.32

0.82 (1.62%)

07:02
04/22/19
04/22
07:02
04/22/19
07:02
Downgrade
Sensata rating change  »

Sensata downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

MDR

McDermott

$9.91

-0.58 (-5.53%)

07:02
04/22/19
04/22
07:02
04/22/19
07:02
Hot Stocks
McDermott awarded petrochemicals contract in Kuwait »

McDermott and Kuwait…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 02

    May

STLD

Steel Dynamics

$33.99

-0.16 (-0.47%)

07:01
04/22/19
04/22
07:01
04/22/19
07:01
Earnings
Steel Dynamics reports Q1 EPS 91c, consensus 98c »

Reports Q1 revenue $2.8B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 16

    May

HNI

HNI Corporation

$38.38

0.1 (0.26%)

06:57
04/22/19
04/22
06:57
04/22/19
06:57
Earnings
HNI Corporation reaffirms FY19 EPS view $2.50-$2.90, consensus $2.66 »

The company stated,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 07

    May

TSM

TSMC

$45.38

1.01 (2.28%)

06:56
04/22/19
04/22
06:56
04/22/19
06:56
Periodicals
TSMC CEO says 7nm utilization rate to rise in 2H19, Digitimes reports »

TSMC's 7nm process…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HNI

HNI Corporation

$38.38

0.1 (0.26%)

06:55
04/22/19
04/22
06:55
04/22/19
06:55
Earnings
HNI Corporation reports Q1 non-GAAP EPS 2c, consensus 1c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 07

    May

BMS

Bemis

$55.45

-0.37 (-0.66%)

06:55
04/22/19
04/22
06:55
04/22/19
06:55
Hot Stocks
Amcor to sell plants to Tekni-Plex for $215M to resolve antitrust concerns »

Amcor and Bemis, as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 18

    May

EGRX

Eagle Pharmaceuticals

$47.81

0.67 (1.42%)

06:54
04/22/19
04/22
06:54
04/22/19
06:54
Hot Stocks
Eagle Pharma announces CMS established unique J-code for BELRAPZO »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$115.20

-1.23 (-1.06%)

06:53
04/22/19
04/22
06:53
04/22/19
06:53
Hot Stocks
Eli Lilly announces Taltz meets primary, secondary endpoints in COAST-X study »

Eli Lilly announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 30

    Apr

  • 04

    May

  • 06

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

CBU

Community Bank System

$62.22

-1.385 (-2.18%)

06:51
04/22/19
04/22
06:51
04/22/19
06:51
Earnings
Community Bank System reports Q1 operating EPS 81c, consensus 76c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 15

    May

TSLA

Tesla

$273.25

2.13 (0.79%)

, PCRFY

Panasonic

$0.00

(0.00%)

06:51
04/22/19
04/22
06:51
04/22/19
06:51
Periodicals
Tesla CEO takes on Panasonic in public dispute with key supplier, Bloomberg says »

Tesla (TSLA) CEO Elon…

TSLA

Tesla

$273.25

2.13 (0.79%)

PCRFY

Panasonic

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

HAL

Halliburton

$31.12

-0.47 (-1.49%)

06:49
04/22/19
04/22
06:49
04/22/19
06:49
Hot Stocks
Halliburton CEO says 'results for the first quarter played out as we expected' »

"Our results for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 06

    May

  • 15

    May

  • 22

    May

  • 29

    May

  • 13

    Nov

BOH

Bank of Hawaii

$80.76

-1.16 (-1.42%)

06:48
04/22/19
04/22
06:48
04/22/19
06:48
Earnings
Bank of Hawaii reports Q1 EPS $1.43, consensus $1.36 »

Reports Q1 net loans and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 26

    Apr

MRK

Merck

$73.19

-0.69 (-0.93%)

06:48
04/22/19
04/22
06:48
04/22/19
06:48
Hot Stocks
Merck: FDA approves KEYTRUDA in combination with Inlyta »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 30

    Apr

  • 03

    May

  • 04

    May

  • 06

    May

  • 18

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 16

    Jul

  • 06

    Aug

  • 20

    Sep

HAL

Halliburton

$31.12

-0.47 (-1.49%)

06:45
04/22/19
04/22
06:45
04/22/19
06:45
Earnings
Halliburton reports Q1 adjusted EPS 23c, consensus 22c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 06

    May

  • 15

    May

  • 22

    May

  • 29

    May

  • 13

    Nov

06:45
04/22/19
04/22
06:45
04/22/19
06:45
General news
FX Update: The dollar majors have been plying narrow ranges »

FX Update: The dollar…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.